• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

How Can the Myeloma Community Reduce Disparities in Care?

by Sabrina Ahle | Jun 14, 2021 | Myeloma News

Source: Multiple Myeloma – ASH Clinical News In our March 2021 issue, we reported on findings from a review article examining disparities in outcomes among patients with multiple myeloma (MM), in which the authors found that Hispanic and non-Hispanic Black patients...

Lenalidomide and Dexamethasone for Older Patients With Multiple Myeloma: Less Is More

by Sabrina Ahle | Jun 14, 2021 | Myeloma News

Source: Multiple Myeloma – ASH Clinical News According to a study published in Blood, older patients with multiple myeloma (MM) who are taking continuous lenalidomide-dexamethasone (Rd) may be able to switch to reduced-dose lenalidomide maintenance without...

Idecabtagene Vicleucel Approved for Relapsed or Refractory Multiple Myeloma

by Sabrina Ahle | Jun 14, 2021 | Myeloma News

Source: Multiple Myeloma – ASH Clinical News The FDA has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed or refractory...

Tandem High-Dose Influenza Vaccine Offers Durable Seroprotection for Patients With Plasma Cell Dyscrasias

by Sabrina Ahle | Jun 14, 2021 | Myeloma News

Source: Multiple Myeloma – ASH Clinical News Tandem high-dose influenza vaccination may result in more durable serologic immunity in patients with plasma cell dyscrasias (PCDs), compared with standard vaccination, according to findings published in Blood Advances....

Idecabtagene Ciloleucel Induces Deep Responses in Relapsed/Refractory Multiple Myeloma

by Sabrina Ahle | Jun 14, 2021 | Myeloma News

Source: Multiple Myeloma – ASH Clinical News Treatment with the B-cell maturation antigen−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene ciloleucel (ide-cel) showed encouraging efficacy in patients with heavily pretreated relapsed and/or...
« Older Entries
Next Entries »

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT